Mr. Eknath Kole M.S. Pharm (NIPER Mohali)

Similar documents
Antiarrhythmic Drugs 1/31/2018 1

Arrhythmias. Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium.

Arrhythmias. 1. beat too slowly (sinus bradycardia). Like in heart block

Chapter 14. Agents used in Cardiac Arrhythmias

PHARMACOLOGY OF ARRHYTHMIAS

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

Antiarrhythmic Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2017

Antiarrhythmic Drugs

Antiarrhythmic Drugs Öner Süzer

Antiarrhythmics 17 I. OVERVIEW II. INTRODUCTION TO THE ARRHYTHMIAS

B. 14 Antidysrhythmic drugs. a. Classify antidysrhythmics by their electrophysiological actions. Vaughan-Williams classification

Chapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy

Chapter 26. Media Directory. Dysrhythmias. Diagnosis/Treatment of Dysrhythmias. Frequency in Population Difficult to Predict

Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014

Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital

ANTI-ARRHYTHMICS AND WARFARIN. Dr Nithish Jayakumar

This document does not consider management of individual arrhythmias look elsewhere, e.g. OHCM.

Antiarrhythmic Drugs Öner Süzer

ARRHYTHMIA SINUS RHYTHM

Antiarrhythmias. Edward JN Ishac, Ph.D. Smith Building, Room

ANTI - ARRHYTHMIC DRUGS

Antidysrhythmics HST-151 1

Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification

DECLARATION OF CONFLICT OF INTEREST. Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical

Pediatrics ECG Monitoring. Pediatric Intensive Care Unit Emergency Division

Atrial Fibrillation 10/2/2018. Depolarization & ECG. Atrial Fibrillation. Hemodynamic Consequences

ELECTRICAL SIGNALS CONTROL THE CARDIAC ACTIVITY

Alaska Nurse Practitioner Annual Conference 2009

Heart Failure (HF) Treatment

Pharmacology: Arrhythmias PC PHPP 515 (IT I) Fall JACOBS Wed, Dec. 03 4:00 5:50 PM

Antiarrhythmic Pharmacology. The Electronics

The most common. hospitalized patients. hypotension due to. filling time Rate control in ICU patients may be difficult as many drugs cause hypotension

Pharmacotherapy of Antiarrhythmias

ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C

! YOU NEED TO MONITOR QT INTERVALS IN THESE PATIENTS.

Dysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias

Fundamentals of Pharmacology for Veterinary Technicians Chapter 8

Atrial fibrillation in the ICU

ARRHYTHMIAS IN THE ICU

ARRHYTHMIAS IN THE ICU: DIAGNOSIS AND PRINCIPLES OF MANAGEMENT

Arrhythmic Complications of MI. Teferi Mitiku, MD Assistant Clinical Professor of Medicine University of California Irvine

Adenosine. poison/drug induced. flushing, chest pain, transient asystole. Precautions: tachycardia. fibrillation, atrial flutter. Indications: or VT

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy

Anti arrhythmic drugs. Hilal Al Saffar College of medicine Baghdad University

Chapter (9) Calcium Antagonists

Cardiac arrhythmias. Janusz Witowski. Department of Pathophysiology Poznan University of Medical Sciences. J. Witowski

Rate and Rhythm Control of Atrial Fibrillation

Intraoperative and Postoperative Arrhythmias: Diagnosis and Treatment

WHAT DO YOU SEE WHEN YOU STIMULATE BETA

Current Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine

Advanced Cardiac Life Support

ALS MODULE 7 Pharmacology

The pill-in-the-pocket strategy for paroxysmal atrial fibrillation

3/25/2017. Program Outline. Classification of Atrial Fibrillation

Heart Failure. Dr. Alia Shatanawi

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

Drugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia

1 Cardiology Acute Care Day 22 April 2013 Arrhythmia Tutorial Course Material

How do arrhythmias occur?

I have nothing to disclose.

PHARMACOLOGY. Drugs Acting on Cardiovascular System: Antiarrhythmic Drugs

PEDIATRIC SVT MANAGEMENT

Core Content In Urgent Care Medicine

Atrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal

ANESTHESIA DRUG REVIEW

Objectives: This presentation will help you to:

2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist

2) Heart Arrhythmias 2 - Dr. Abdullah Sharif

CVD: Cardiac Arrhythmias. 1. Final Cardiac Arrhythmias_BMP. 1.1 Cardiovascular Disease. Notes:

3. AV Block 1. First-degree AV block 1. Delay in AV node 2. Long PR interval 3. QRS complex follows each P wave 4. Benign, no tx

Case #1. 73 y/o man with h/o HTN and CHF admitted with dizziness and SOB Treated for CHF exacerbation with Lasix Now HR 136

Dr. Hussam Al-Humadi. Cardiac Arrhythmia

ECGs and Arrhythmias: Family Medicine Board Review 2009

CORDARONE Sanofi-Aventis

CORONARY ARTERIES. LAD Anterior wall of the left vent Lateral wall of left vent Anterior 2/3 of interventricluar septum R & L bundle branches

Management of Postoperative Atrial Fibrillation

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Where are the normal pacemaker and the backup pacemakers of the heart located?

Amiodarone Prescribing and Monitoring: Back to the Future

4/14/15 HTEC 91. Topics for Today. Guess That Rhythm. Premature Ventricular Contractions (PVCs) Ventricular Rhythms

Are Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist

Review Article Drug Therapy Considerations in Arrhythmias in Children

Dysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics

EKG Rhythm Interpretation Exam

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

AF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire

Cardiac Arrhythmias. For Pharmacists

Document 3 Summary of Data and Guidance for Medical Professionals

7/21/2017. Learning Objectives. Current Cardiovascular Pharmacology. Epinephrine. Cardiotonic Agents. Epinephrine. Epinephrine. Arthur Jones, EdD, RRT

Practical Approach to Arrhythmias

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

2/1/2013. Poisoning pitfalls. The original pitfall

EKG Competency for Agency

ARRHYTHMIAS IN THE INTENSIVE CARE UNIT

Arrhythmias (I) Supraventricular Tachycardias. Disclosures

Medical management of AF: drugs for rate and rhythm control

Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh

Review Packet EKG Competency This packet is a review of the information you will need to know for the proctored EKG competency test.

Understanding Atrial Fibrillation Management. Roy Lin, MD

Transcription:

M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization -Inhibits K+ channels -Mild α-adrenergic blocking action -Atropine-like effect -Atrial tachy -Av-junctional tachy - Ventricular -Maintains sinus rhythm after direct-current cardioversion -Prevent frequent ventricular -Rapidly and completely absorbed after oral administration - Extensive metabolism by CYP450 -Polymorphic ventricular tachy (torsades de pointes) -SA and AV block -Asystole -Toxic: ventricular -Nausea -Vomiting -Diarrhea -Cinchonism (blurred vision, tinnitus, headache, disorientation, psychosis) -Has class III activity as well -Cardiotoxic effects are exacerbated by hyperkalemia - Increases steadystate concentration of DIGOXIN by displacing it from tissues and decreasing its renal clearance Procainamide IA -Binds to open and inactivated Na+ -NAPA: prolongs the duration of the action potential (class III actions) -Well absorbed after oral administration -1/2 life: 2-3 hours -Acetylated in liver to NAPA -NAPA eliminated via kidneys -SLE like syndrome -Asystole -Ventricular -Depression -Hallucination -Psychosis -Dosage needs to be adjusted in patients with renal failure Disopyramide IA -Binds to open and inactivated Na+ -Negative inotropic effect (decrease in contractility) is stronger than QUINDINE and PROCAINAMIDE -Peripheral vasoconstriction -Ventricular -50% excreted in urine unchanged -30% of the drug converted by liver to mono-n-dealkylated metabolite -Dry mouth -Urinary retention -Blurred vision -Constipation -Has Class III activity

M.S. Pharm (NIPER Mohali) Lidocaine IB -Rapidly associates and dissociates from NA+ channels -Actions are manifested when cardiac cell is depolarized or firing rapidly - Shortens Phase 3 repolarisation and decreases the duration of AP -Ventricular arising during myocardial ischemia -Given via IV due to extensive 1 st pass metabolism -Wide therapeutic index -Drowsiness -Slurred speech -Paresthesia -Agitation -Confusion -Convulsions -Local anesthetic - Dose should be adjusted in people with liver dysfunction -Cardiac Mexiletine Tocainide IB -Shortens Phase 3 repolarisation and decreases the duration of AP -Mexiletine: chronic tx of ventricular associated w/ previous MI Tocainide: tx of ventricular tachy -Tocainide: pulmonary toxicity leading to pulmonary fibrosis Flecainide IC -Slowly dissociate from resting Na+ channels -Prominent effects even at normal heart rates -Suppresses Phase ) upstroke in Purkinje and myocardial fibers Slowing of conduction in all cardiac tissue -Automaticity is reduced by an increase in the threshold potential -Refractory ventricular -Prevention of paroxysmal atrial fibrillation/flutter - Paroxysmal -Suppresses premature ventricular contraction -Absorbed orally -1/2 life: 16-20 hours -Dizziness -Blurred vision -Headache -Nausea -Aggravates pre-existing -Induces ventricular -Negative inotropic effects can aggravate CHF Propafenone IC -Slows conduction in all cardiac tissues -Broad spectrum antiarrhythmic agent

M.S. Pharm (NIPER Mohali) β-antagonists Propranolol Metoprolol Esmolol II -Diminish Phase 4 depolarization depressing automaticity, prolonging AV conduction and decreasing HR and contractility -Tachy caused by increased sympathetic activity - Atrial flutter and fibrillation -AV-nodal re-entrant -Esmolol: acute during surgery or emergency situations -Propranolol: reduces incidence ofsudden arrhythmic death after MI -Metoprolol: reduces the risk of bronchospasm; most widely used in treatment of cardiac Amiodarone III -Prolongs the action potential duration and the refractory period -Severe refractory and ventricular tachy -Incompletely absorbed after oral administration -Prolonged ½ life of several weeks -Interstitial pulmonary fibrosis -GI intolerance -Tremor -Has Class I, II, IV actions as well -Also has antianginal actions -Extensive distribution in adipose tissue -Full clinical effects achieved 6 weeks after initiation of therapy -Ataxia -Dizziness -Hyper- or hypothyroidism -Liver toxicity -Photosensitivity -Neuropathy -Muscle weakness -Blue skin discoloration

M.S. Pharm (NIPER Mohali) Sotalol III -Has potent nonselective β-blocker activity (suppresses ectopic beats, reduces myocardial oxygen demand, antifibrillatory effects ) -Blocks rapid outward K+ current (delayed rectifier) prolongs both repolarisation and duration of AP Lengthening effective refractory period -Prevents recurrence of -Decreased mortality in patients with sustained ventricular -Torsade de pointes Dofetilide III -1 st line agent in pts with persistent atrial fibrillation and HF -CAD w/ impaired LV function -1/2 life 10 hours -Excreted in urine -AMIODARONE, β- BLOCKERS AND DOFETILIDE are the only antiarrhythmic drugs recommended for tx of atrial fibrillations Verapamil Diltiazem IV -Block voltage-sensitive Ca 2+ channels Decrease in slow inward current that triggers cardiac contraction Slow conduction and prolong effective refractory period -Bind only to open, depolarized channels, preventing repolarisation until the drug dissociates -Block most effectively when the heart is rapidly beating (use-dependent) -Arrhythmias that traverse Ca 2+ dependent cardiac tissues -Atrial -Reentrant -Reduce ventricular rate it atrial flutter and fibrillation -HTN -Absorbed well after oral administration - Verapamil: extensively metabolized by liver -Decrease BP -contraindicated in pts with pre-existing depressed cardiac function (due to negative inotropic effects)

M.S. Pharm (NIPER Mohali) -Angina Digoxin -Shortens the refractory period in atrial and ventricular myocardial cells -Prolongs the effective refractory period and diminishes conduction velocity in the AV node -Control ventricular response rate in atrial fibrillation and flutter -Ectopic ventricular beats Ventricular and fibrillation (treated with LIDOCAINE OR PHENYTOIN) Adenosine -Decreases conduction velocity -Prolongs refractory period -Decreases automaticity in the AV node -DOC: abolishing acute -Short duration of action: 15 seconds -Flushing -Chest pain -Hypotension -Naturally occurring nucleoside